List of Excipients in Branded Drug IXEMPRA

✉ Email this page to a colleague

IXEMPRA (ixabepilone) excipient strategy and commercial opportunities: formulation IP, supply leverage, and generic/biosimilar risk map

Last updated: May 31, 2026

IXEMPRA is formulated as a lyophilized powder for injection and reconstituted with diluent containing polysorbate 80 and dehydrated alcohol (commercial products in this class use surfactant/solvent excipient systems to solubilize hydrophobic taxane-like agents). The commercial opportunity for new entrants is shaped less by the active ingredient patent estate and more by formulation, reconstitution, and container closure system (CCS) IP that governs stability, solubilization, and compatibility, plus FDA CMC readiness for sterility, particle control, and reconstitution performance.

What excipients are used in IXEMPRA and why do they matter for formulation IP?

IXEMPRA is marketed in a vial-based lyophilized format designed to deliver axial solubility and stability for ixabepilone, a poorly soluble, hydrophobic drug. The excipient system is central to three value drivers:

Solubilization and reconstitution
Surfactant and co-solvent excipients reduce aggregation and precipitation after reconstitution. This drives usable shelf life at the bedside and limits dosing variability.
Stability under stress and shipping
Lyophilization excipients (commonly including cryo/lyoprotectants and bulking agents) protect the amorphous drug phase and limit chemical degradation during storage and transport.
Administration compatibility
CCS and diluent composition affect leachables/extractables, adsorption to plastic, and particle burden. These factors can become the basis for non-interchangeability claims versus competitor products.

Which excipient functions dominate IXEMPRA formulations?

Formulation strategy for hydrophobic oncology agents in lyophilized vials typically partitions into:

Lyoprotectant and bulking agents: stabilize the solid state during freeze-drying and control cake morphology.
Surfactant system: maintains solubilization in aqueous infusion conditions and reduces micelle destabilization during dilution.
Co-solvent/dehydrated alcohol: increases apparent solubility and supports rapid reconstitution.
Buffering and pH control: reduce chemical degradation pathways and ensure tolerability.

Where does excipient strategy create enforceable IP?

Excipient strategy creates patent “pressure points” in:

Reconstitution method and diluent composition claims (surfactant/co-solvent concentration ranges).
Lyophilized cake composition (specific ratios of cryoprotectant/bulking agents).
Stabilizer systems that control degradation products under ICH stress conditions.
CCS and compatibility claims, especially around adsorption and subvisible particle generation.

Practical point for commercial entrants: if ixabepilone composition-of-matter patents are near expiration or already expired, formulation and reconstitution IP becomes the primary barrier to a straightforward generic launch and can support “at-risk” entry timelines.

What patents protect IXEMPRA excipients, reconstitution, and injection formulation?

A complete, accurate IXEMPRA excipient patent map requires current Orange Book listings and associated patent documents. Without those listings and patent numbers, a definitive claim chart covering excipients, diluent composition, and CCS cannot be produced.

What categories of patents usually cover excipient systems for lyophilized oncology injectables?

When innovators secure exclusivity around excipient systems, patents often target:

Lyophilized pharmaceutical composition: composition claims listing drug plus specific excipients and weight ratios.
Reconstitution composition and method: diluent composition and reconstitution time/temperature conditions.
Stabilization and particle control: controlling subvisible particles and aggregation during infusion.
Container closure system: compatibility-related claims, including vial stopper composition and draw/withdraw performance.
Use-related patents are separate from excipient patents, but method-of-use claims can block labeling changes.

What to assume for IXEMPRA?

IXEMPRA’s excipient strategy is consistent with a defensible formulation approach used for hydrophobic chemotherapeutics: protect how the drug is rendered soluble and stable, not just the active molecule. Commercial opportunities typically cluster around:

reformulation that maintains pharmacokinetic and safety equivalence but avoids claim scope,
licensed manufacturing that adopts the pioneer’s excipient system under agreement,
and “authorized generic” pathways where formulation IP remains a business constraint.

When does IXEMPRA lose exclusivity: drug substance, formulation, and regulatory exclusivity timelines?

A precise exclusivity timeline needs the Orange Book patent list for IXEMPRA drug products and their expiration dates, plus any relevant pediatric exclusivity or additional FDA exclusivity grants tied to the NDA and supplements.

What timeline components control “when generics can launch”?

For injectable small molecules, the generic launch trigger typically depends on:

composition-of-matter patent expiry on ixabepilone (drug substance),
formulation and method patents on the lyophilized/reconstituted product,
FDA regulatory exclusivity (if applicable) tied to the original approval or later line extensions,
any orphan/pediatric exclusivity or exclusivity tied to manufacturing changes,
and whether ANDAs must use Section viii carve-outs or change excipient systems (which can create bioequivalence/CMC challenges for complex injectables).

Commercial implication for excipient strategy

Even when drug substance patents expire, formulation and reconstitution patents can extend effective market protection by blocking FDA approval pathways or by creating litigation risk for Paragraph IV filers. That shifts commercial opportunity toward:

licensing formulation know-how and excipient sourcing,
contract manufacturing that can support narrow ranges for critical excipients,
and reformulation strategies that deliberately design around claim scope.

What generic entry risks exist for IXEMPRA under Paragraph IV challenges?

Risk depends on the presence and enforceability of:

formulation patents (lyophilized composition, diluent composition, reconstitution method),
and method-of-use patents that could constrain labeling.

How excipients change the Paragraph IV landscape

For hydrophobic injectables, generic risk can be higher because:

excipient composition affects solubilization and particle formation, not just drug release,
formulation equivalence often requires robust bridging studies, and
small changes in surfactant/co-solvent ratios can trigger stability or CMC failures.

Commercial pathways that reduce Paragraph IV exposure

Authorized generic supply via licensing: avoids litigation risk and accelerates market share capture.
Non-Paragraph IV pathways: when patents are absent or cleared via noninfringement/expiration, entrants can file and launch with fewer hurdles.
Design-around formulation: if excipient patents exist, entrants can shift excipient system composition while maintaining performance.

How strong is the patent estate for IXEMPRA: formulation vs method-of-use vs process?

Strength cannot be scored without:

specific IXEMPRA patent numbers,
their expiration dates,
and claim breadth tied to excipient ranges and reconstitution methods.

What “strong formulation estate” usually looks like

multiple continuation filings that keep narrow excipient ranges active,
claims anchored to specific diluent composition and reconstitution procedure,
process-related claims for freeze-drying cycle parameters and particle control,
and CCS compatibility claims.

What “weak formulation estate” looks like

only broad drug substance claims,
excipient claims that map to ranges already common in industry,
or weak claim drafting that allows easy design-around.

What formulations are protected by IXEMPRA patents: lyophilized vial vs ready-to-use?

IXEMPRA is a lyophilized injectable product; commercial alternatives in the market could target:

ready-to-use liquid formats (if solvent stability permits),
alternative diluent systems,
different lyophilization protectant systems.

Where substitution creates commercial opportunity

If competitors can develop:

a liquid that matches solubilization and stability without infringing excipient composition claims, or
a different lyophilized excipient system that reduces reliance on the pioneer’s specific ranges, then an entrant may compete on:
reduced reconstitution burden,
improved infusion workflow,
improved stability at typical clinical handling temperatures,
and lower manufacturing cost (if lyophilization cycle constraints can be optimized).

Which companies are challenging IXEMPRA and what litigation affects excipient strategy?

A company-by-company challenge and litigation map requires:

the ANDA Paragraph IV filer list for ixabepilone,
court docket outcomes,
and any settlement agreements tied to launch dates.

Without Orange Book and litigation data tied to IXEMPRA’s specific NDA/product strength and form, a complete and accurate listing cannot be produced.

What is the Orange Book status of IXEMPRA and how does it guide formulation design-around?

Orange Book status drives:

whether patents are listed for the specific strength and dosage form,
which patents are “listed” versus “withdrawn,”
whether there are multiple active patents in each category (drug substance, drug product/formulation, method-of-use).

How to use Orange Book status to build an excipient strategy

For hydrophobic injectables, design-around typically targets the claim “hooks”:

surfactant identity and concentration,
co-solvent identity and concentration,
lyoprotectant identity and ratio,
reconstitution instructions (time, temperature, mixing),
and compatibility constraints (infusion diluent and administration set).

How does IXEMPRA compare with similar hydrophobic chemotherapeutics on excipient approach and commercial opportunity?

Commercial comparison for excipient strategy typically compares lyophilized hydrophobic agents using surfactant/co-solvent systems and lyoprotectants. The opportunity pattern is consistent across:

taxane-like hydrophobic drugs,
epothilone-like agents,
and other insoluble oncology small molecules.

Key competitive levers

Reconstitution time: shorter time improves clinic workflow and reduces handling errors.
Particle and opacity profiles: subvisible particle control supports safer infusion and fewer product holds.
Shelf life post-reconstitution: extends inpatient/outpatient use windows.
Stability in shipping: reduces recalls and increases manufacturing predictability.
Cost of goods: excipient availability and lyophilization cycle efficiencies drive margins.

Commercial opportunities for excipient innovation in IXEMPRA: where value accrues

Without market revenue or contract structure data tied to IXEMPRA, the opportunity analysis focuses on formulation commercialization levers that directly affect manufacturing, regulatory approval, and market access.

Opportunity 1: Licensed supply of the pioneer excipient system

When formulation IP remains enforceable, the most reliable route is licensing:

excipient sourcing specifications,
critical process parameters for lyophilization,
QC acceptance criteria for particle control and reconstitution performance,
and validated dilution compatibility.

Business value: reduced regulatory risk and fastest time to market for authorized supply.

Opportunity 2: Design-around excipient system that maintains solubilization

A competitor can pursue:

alternative surfactant/co-solvent combinations that achieve comparable micellar solubilization,
alternative lyoprotectants to stabilize the solid state,
revised reconstitution with equivalent performance.

Business value: enable generic-like competition where claim scope permits, while differentiating on administration experience and stability.

Opportunity 3: Improve clinical usability without changing pharmacology

Packaging and usability improvements often generate commercial impact even when active substance remains unchanged:

reduce reconstitution steps,
improve syringe/vial compatibility,
extend post-reconstitution time under label conditions.

Business value: formulary adoption and procurement advantage if safety and handling improve.

Opportunity 4: Manufacturing risk reduction

Lyophilized injectables can face:

variability in cake structure,
residual moisture control challenges,
and batch-to-batch reconstitution performance drift.

Business value: proprietary freeze-drying process improvements and tighter excipient specs can reduce lot rejection and cost of goods.

Key compliance and CMC requirements tied to excipient changes for IXEMPRA-like injectables

Excipient strategy is not only IP. It is also CMC and patient safety.

What regulators focus on for lyophilized hydrophobic injectables

Reconstitution performance: complete dissolution, absence of particulates, and controlled viscosity.
Stability: potency and degradation products during storage and post-reconstitution.
Particle characterization: subvisible particle burden and clarity/opacity.
Compatibility: adsorption to infusion set and adsorption to container surfaces.
Leachables/extractables: vial/stopper materials and surfactant interactions.

For any excipient design-around, these are the binding constraints that determine whether a formulation can be approved.

Key Takeaways

IXEMPRA’s value-protecting formulation core is its lyophilized, reconstituted injection system, where surfactant/co-solvent solubilization and lyophilization protectant stability drive both safety and IP leverage.
For commercial entrants, the highest-impact opportunities and risks lie in excipient composition, reconstitution/diluent systems, and CCS compatibility, not only in ixabepilone’s drug substance exclusivity.
Generic entry risk under Paragraph IV is typically elevated for hydrophobic lyophilized oncology injectables because excipients affect solubilization, particle control, and CMC equivalence.
The practical commercial playbook centers on licensing the pioneer excipient/process package or pursuing claim-scoped design-around excipient systems while meeting strict reconstitution and particle characterization requirements.

FAQs

1) What excipient changes are most likely to trigger a CMC failure for hydrophobic lyophilized injectables?
Surfactant/co-solvent identity or concentration shifts, lyoprotectant ratio changes that alter cake morphology, and changes that impact reconstitution clarity or subvisible particle profiles.

2) Can a generic of a lyophilized hydrophobic oncology drug differ in excipients and still be approved?
Yes in principle, but approval hinges on demonstrating equivalence in reconstitution performance, stability, and particle safety, and on navigating formulation patent scope.

3) How do container closure components influence excipient performance in IXEMPRA-like products?
Vial/stopper materials affect adsorption and leachables/extractables, which can change apparent solubility behavior and particle burden in infusion.

4) What is the commercial advantage of optimizing lyophilization cycle parameters?
It reduces batch variability, improves cake reproducibility, and stabilizes post-reconstitution performance, lowering lot rejection and cost of goods.

5) What is the best business model when formulation IP blocks a direct generic launch?
Authorized supply via licensing, combined with manufacturing transfer of the validated excipient and process package.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. Drug Approval Package (IXEMPRA, ixabepilone) and labeling. FDA.
FDA. Guidance for Industry: ANDAs: Technical Conformance and Product Quality Information. FDA.

More… ↓

⤷ Start Trial